1. Hennekens CH. Increasing global burden of cardiovascular disease; current knowledge and future directions for research on risk factors. Special report. Circulation. 1998;97:1095–102.
2. Hennekens CH, Dalen JE. Aspirin in the treatment and prevention of cardiovascular disease: Past and current perspectives and future directions. Am J Med. 2013;126(5):373–8.
3. Antithrombotic Trialists Collaboration, Barnett H, Bousser M-G, Boysen G, Breddin K, Britton M, Buring J, Cairns J, Canner P, Collins R, Cortellaro M, Daniels A, Deykin D, Elwood P, Elwin E-E, Eschwege E, Farrell B, Fields WS, Gent M, Gray R, Guiraud-Chaumeil B, Hennekens CH, Klimt C, Lewis HD, Loria Y, Lowenthal A, MacMahon C, Miller J, Peto R, Qizilbash N, Reuther R, Richards S, Rosen A, Sandercock P, Sorensen PS, Sweetnam D, Taylor W, Thibult N, van Gijn J, Vogel G, Warlow C, Yusuf S. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high-risk patients. Br Med J. 2002;24:71–86.
4. Hebert PR, Pfeffer MA, Hennekens CH. Use of statins and aspirin to reduce cardiovascular disease. J Cardiovasc Pharmacol Ther. 2002;7:77–80.
5. Hennekens CH, Sacks F, Tonkin A, Jukema W, Byington RP, Pitt B, Berry DA, Berry SM, Ford NF, Walker AJ, Nataragan K, Sheng-Lin C, Fiedorek FT, Belder R. Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: Randomized and observational comparisons of secondary prevention trials and their meta-analysis. Arch Intern Med. 2004;164(1):40–4.